Table 1. Characteristics of studies included in the network meta-analysis.
| Study | Size | Follow-up (month) |
Disease Stage | Age | Male (%) | Radiotherapy | Chemotherapy | ||
|---|---|---|---|---|---|---|---|---|---|
| Type | Dose/Gy | Intervention 1 | Intervention 2 | ||||||
| Al-Sarraf, 1998 | 193 | 30 | AJCC III–IV,WHO I-III | 50 | 67.0 | RT | 70 | C (cisplatin) + A (fluorouracil, cisplatin) | Control |
| Cao, 2015 | 180 | 58.97 | AJCC II–III | 47 | 73.0 | IMRT | 70 | C (cisplatin) | Control |
| Chan, 1995 | 82 | 28.5 | WHO III | 44 | 92.0 | RT | 58-66 | N (fluorouracil, cisplatin) | Control |
| Chan, 2005 | 350 | 66 | WHO I-III,UICC II-IV | 45 | 80.0 | RT | 66 | C (cisplatin) | Control |
| Chen, 2008 | 316 | 29 | AJCC III–IVb | 46 | 73.4 | RT | 70 | C (cisplatin) + A (fluorouracil, cisplatin) | Control |
| Chen, 2011 | 220 | 60 | AJCC II–III,WHO II-III | 42 | 70.7 | RT | 68-70 | C (cisplatin) | Control |
| Chen, 2012 | 508 | 37.8 | WHO III-IVb | 44 | 77.0 | RT | 66 | C (cisplatin) + A (fluorouracil, cisplatin) | C (cisplatin) |
| Chi, 2002 | 157 | 49.5 | WHO I-III | 46 | 77.9 | RT | 70.2 | A (leucovorin, fluorouracil, cisplatin) | Control |
| Chua, 1998 | 334 | 30 | AJCC I–IV,M0 | 47 | 75.0 | RT | 71 | N (epirubicin, cisplatin) | Control |
| Cvitkovic, 1996 | 339 | 49 | WHO I-III,M0 | 42 | 75.0 | RT | 65-70 | N (bleomycin, epirubicin, cisplatin) | Control |
| Ding, 2011 | 56 | 3 | TNM II-IV | 48 | 60.7 | RT | 70 | C (cisplatin) + A (fluorouracil, cisplatin) | C (cisplatin) |
| Fountzilas, 2012 | 141 | 55 | WHO I-III | 49 | 71.0 | RT | 70 | N (epirubicin, cisplatin, paclitaxel) + C (cisplatin) | C (cisplatin) |
| Ge, 2009 | 52 | - | TNM II-III | 54 | 76.9 | RT | 70 | C (CMNa) | Control |
| Guan, 2016 | 69 | 35 | AJCC I–IV,WHO II-III | 48 | 85.7 | IMRT | 60 | C (cisplatin) | Control |
| Hareyama, 2002 | 80 | 49 | WHO I-III | 50 | 75.0 | RT | 66-68 | N (fluorouracil, cisplatin) | Control |
| Huang, 2012 | 200 | - | WHO II-III | 44 | 56.0 | RT | 66-78 | N (fluorouracil, carboplatin) + C (carboplatin) | C (carboplatin) |
| Huang, 2015 | 408 | 133.3 | UICC II-IV | 45 | 77.6 | RT | 66-78 | N (floxuridine, carboplatin) + C (carboplatin) | N (floxuridine, carboplatin) |
| Hui, 2009 | 65 | - | UICC III-IV | 50 | 61.8 | RT | 78.4 | N (docetaxel, cisplatin) + C (cisplatin) | C (cisplatin) |
| Kong, 2015 | 200 | - | WHO III-IV | 50 | 63.0 | RT | 66-75 | C (fluorouracil) | Control |
| Kwong, 2004* | 219 | 37 | AJCC II–IV,WHO I-III | 45 | 69.1 | RT | 66 | C (uracil, tegafur) | Control |
| A (fluorouracil, cisplatin, vincristine, bleomycin, methotrexate) |
C (uracil, tegafur) + A (fluorouracil, cisplatin , vincristine, bleomycin, methotrexate) |
||||||||
| Lai, 2007 | 95 | - | TNM I-IV | 51 | 76.6 | RT | 70-80 | C (CMNa) | Control |
| Lee, 2010 | 348 | 60 | WHO III-Ivb | 46 | 72.0 | RT | 68 | C (cisplatin) + A (fluorouracil, cisplatin) | Control |
| Lee, 2011 | 441 | 73.2 | WHO III-IVb | 46 | 74.0 | RT | 66 | C (cisplatin) + A (fluorouracil, cisplatin) | Control |
| Liang, 2008 | 72 | - | TNM I-IV | 62.2 | RT | 60-70 | C (CMNa) | Control | |
| Liao, 2008 | 48 | - | TNM II-IV | 51 | 58.3 | RT | 68-74 | C (CMNa) | Control |
| Lin, 2003 | 284 | 65 | WHO I-III | 45 | 71.6 | RT | 70-74 | C (fluorouracil, cisplatin) | Control |
| Liu, 2006 | 211 | 52 | TNM I-IV | 46 | 88.5 | RT | 68-70 | C (CMNa) | Control |
| Liu, 2010 | 44 | - | TNM III-IVa | 51 | 72.7 | RT | 72-74 | C (CMNa) | Control |
| Ma, 2001 | 456 | 62 | WHO I-III | 46 | 69.0 | RT | 68-72 | N (bleomycin, fluorouracil, cisplatin) | Control |
| Ma, 2009 | 98 | 24 | TNM III-Iva | 48 | 77.6 | RT | 70 | N (fluorouracil, cisplatin, paclitaxel) + C (fluorouracil, cisplatin) |
C (fluorouracil, cisplatin) |
| Rossi, 1988 | 229 | - | T1-4,N0-3 | 49 | 70.0 | RT | 60-70 | A (vincristine, cyclophosphamide, adriamycin) | Control |
| Ruste, 2011 | 30 | - | WHO III-IVb | 36 | 62.5 | RT | 70 | C (cisplatin) + A (fluorouracil, cisplatin) | N (fluorouracil, cisplatin) + C (cisplatin) |
| Tan, 2008 | 60 | - | TNM I-Iva | 51 | 50.0 | RT | 68-70 | C (CMNa) | Control |
| Tan, 2015 | 172 | 40.8 | WHO II-III | 49 | 82.6 | IMRT | 70 | N (paclitaxel, gemcitabine) + C (cisplatin) | C (cisplatin) |
| Wang, 2010 | 66 | - | TNM III | 45 | RT | 70-74 | C (CMNa) | Control | |
| Wang, 2014 | 695 | 66.4 | WHO I-II | 45 | 77.7 | IMRT | 67-76 | C (cisplatin) | Control |
| Wee, 2015** | 83 | 49.4 | WHO I-Iib | 49 | 68.7 | IMRT | 67.5 | C (cisplatin) | C (cisplatin) + A (fluorouracil, cisplatin) |
| N (docetaxel, fluorouracil, cisplatin or docetaxel, cisplatin or fluorouracil, cisplatin) + C (cisplatin) |
- | ||||||||
| Wen, 2014 | 60 | - | AJCC III-Ivb | 46 | 57.0 | RT | 60-66 | C (docetaxel) | Control |
| Wu, 2006 | 40 | - | TNM III-IV | 56 | 75.0 | RT | 70-74 | C (CMNa) | Control |
| Wu, 2013 | 115 | 114 | WHO II-III | RT | 70-74 | C (oxaliplatin) | Control | ||
| Wu, 2014 | 35 | 31.9 | UICC III-Ivb,WHO II-III | 36 | 72.2 | RT | 70 | C (H-R3) | Control |
| Xu, 2014 | 338 | 60 | AJCC III-Ivb | 49 | 74.1 | RT | 70-76 | N (fluorouracil, cisplatin) + A (fluorouracil, cisplatin) | C (fluorouracil, cisplatin) + A (fluorouracil, cisplatin) |
| Xu, 2015 | 86 | 37.4 | UICC II-IV | 51 | 72.1 | IMRT | 66 | C (cisplatin) | Control |
| Yang, 2007 | 60 | - | T1-4N0-3M0 | 41 | 66.7 | RT | 60-70 | C (CMNa) | Control |
| Yang, 2012 | 60 | 3 | TNM II-IV | 63 | 73.3 | RT | 72 | C (CMNa) | Control |
| Yi, 2014 | 333 | - | WHO III-IV | 47 | 73.9 | IMRT | 70-74 | C (cisplatin) | Control |
| Zeng, 2014 | 234 | 22 | WHO II-III | 48 | 86.0 | RT | 70 | C (cisplatin) | Control |
| Zhang, 2005 | 115 | 24 | WHO II-III,AJCC III–IV | 46 | 67.8 | RT | 70-74 | C (oxaliplatin) | Control |
| Zhang, 2008 | 100 | - | TNM III-IV | RT | 68-70 | C (CMNa) | Control | ||
| Zhang, 2008 | 45 | - | TNM III-IV | 41 | 80.0 | RT | 70-74 | C (CMNa) | Control |
| Zhang, 2015 | 799 | 55.27 | WHO I-III | 46 | 73.0 | IMRT | 60 | N (docetaxel, paclitaxel, cisplatin or docetaxel, paclitaxel, cisplatin, fluorouracil) + C (cisplatin) |
C (cisplatin) |
| Zhou, 2011 | 60 | - | T2N2M0 | 46 | 80.0 | RT | 70-74 | C (CMNa) | Control |
Kwong, 2004*, four arms study; Wee, 2015**, three arms study; Abbreviations: AJCC, American Joint Committee on Cancer; WHO, World Health Organization; UICC, International Union Against Cancer; TNM, T, Tumor, N, regional lymph node, M, metastasis; RT, radiotherapy; IMRT, intensity-modulated radiotherapy; A, Adjuvant chemotherapy; C, Concurrent chemotherapy; N, Neoadjuvant chemotherapy; CMNa, sodium glycididazole.